Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Cell Immunol. 2020 Jul 15;355:104173. doi: 10.1016/j.cellimm.2020.104173

Table 2.

Experimental contributions to the understanding of the Treg niche

Experimental modality Contributing knowledge
GMCSF-NAg tolerogenic vaccine An intermediate-efficiency antigenic domain favors Treg dominance in vivo.
IFN-β + NAg in Alum tolerogenic vaccine High-zone IFN-β signaling favors Treg dominance in vivo.
IFN-β + NAg induction of murine Tregs High-zone IFN-β signaling favors Treg dominance in vitro.
Continuous stable lines of murine Tregs Low-zone IL-2 signaling favors Treg dominance in vitro.

Zones of antigenic and cytokine signaling appear operative for definition of the Treg niche, including intermediate-efficiency TCR signaling (i.e., intermediate quality of TCR signaling efficacy), high-zone IFN-β signaling (i.e., contingent upon high IFN-β concentrations), and low-zone IL-2 signaling (i.e., contingent upon limiting concentrations of IL-2).